Advanced Life Sciences, a biopharmaceutical company that develops drugs to treat infectious disease, inflammation, and oncology, lowered its proposed price range to $8-$9 from $11-$13 while it upped the number of shares to be offered to 5.0 million from 4.5 million. CE Unterberg Towbin will be the lead manager on the deal. Timing is day-to-day.
